Bicara Therapeutics (BCAX) Net Cash Flow (2023 - 2026)

Bicara Therapeutics' Net Cash Flow history runs 4 years deep, the most recent figure standing at $226.8 million for Q1 2026.

• On a quarterly basis, Net Cash Flow rose 920.29% year-over-year to $226.8 million in Q1 2026; TTM through Mar 2026 was -$138.6 million, a 156.34% decrease from a year earlier, with the FY2025 full-year figure at -$393.0 million, down 251.59% from the prior year.
• Net Cash Flow climbed to $226.8 million in Q1 2026 per BCAX's latest filing, from -$75.0 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $316.9 million in Q3 2024 and bottomed at -$264.9 million in Q3 2025.
• The 4-year median for Net Cash Flow is -$19.9 million (2024), against an average of $27.9 million.
• Across the five-year window, Net Cash Flow slumped 183.6% in 2025 and soared 920.29% in 2026, its largest moves.
• Year by year, Net Cash Flow stood at $186.2 million in 2023, then plunged by 116.67% to -$31.0 million in 2024, then plunged by 141.53% to -$75.0 million in 2025, then soared by 402.42% to $226.8 million in 2026.
• Per Business Quant, the three latest BCAX Net Cash Flow figures stand at $226.8 million (Q1 2026), -$75.0 million (Q4 2025), and -$264.9 million (Q3 2025).